A psychedelics startup has a big vision. Investors aren’t buying it.

Awakn Life Science’s ketamine therapy for alcohol use disorder is promising. Will it be profitable?

British psychiatrist Ben Sessa believes fervently in psychedelic medicines. They are “likely to change the whole paradigm of psychiatry,” says Sessa, who a co-founder and head of…



Psychedelics have enormous potential, for those with mental disorders and for the rest of us. These stories will cover the people and issues driving the psychedelic renaissance.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Marc Gunther

Reporting on psychedelics, tobacco, philanthropy, animal welfare, etc. Ex-Fortune. Words in The Guardian, NYTimes, WPost, Vox. Baseball fan. Runner.